Cover Image
市場調查報告書

乾燥症候群(修格蘭氏症候群) : 開發平台分析

Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 350596
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
乾燥症候群(修格蘭氏症候群) : 開發平台分析 Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 93 Pages
簡介

乾燥症候群(修格蘭氏症候群)是自體免疫疾病,會引起身體分泌腺及其他組織的發炎。症狀有皮疹和乾性皮膚,陰道乾燥,持續性乾咳,慢性疲勞,乾眼症,乾唇,關節痛,腫,僵硬等。原因有老齡化,性別,風濕性疾病等。

本報告提供乾燥症候群(修格蘭氏症候群)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞和發表的企業和研究機關正在開發之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

乾燥症候群(修格蘭氏症候群) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/研究機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

  • Akari Therapeutics, Plc
  • Amgen Inc.
  • Ampio Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • MedImmune, LLC
  • Novartis AG
  • Redx Pharma Plc
  • Toleranzia AB
  • UCB S.A.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8187IDB

Summary

Global Markets Direct's, 'Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016', provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren)
  • The report reviews pipeline therapeutics for Sicca Syndrome (Sjogren) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sicca Syndrome (Sjogren) therapeutics and enlists all their major and minor projects
  • The report assesses Sicca Syndrome (Sjogren) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sicca Syndrome (Sjogren)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Sicca Syndrome (Sjogren) Overview
  • Therapeutics Development
  • Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies
  • Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes
  • Sicca Syndrome (Sjogren) - Pipeline Products Glance
  • Sicca Syndrome (Sjogren) - Products under Development by Companies
  • Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes
  • Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
  • Sicca Syndrome (Sjogren) - Therapeutics Assessment
  • Drug Profiles
  • Sicca Syndrome (Sjogren) - Recent Pipeline Updates
  • Sicca Syndrome (Sjogren) - Dormant Projects
  • Sicca Syndrome (Sjogren) - Discontinued Products
  • Sicca Syndrome (Sjogren) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Sicca Syndrome (Sjogren), H1 2016
  • Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics, Plc, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc., H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Biogen, Inc., H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by MedImmune, LLC, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by Toleranzia AB, H1 2016
  • Sicca Syndrome (Sjogren) - Pipeline by UCB S.A., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Sicca Syndrome (Sjogren) Therapeutics - Recent Pipeline Updates, H1 2016
  • Sicca Syndrome (Sjogren) - Dormant Projects, H1 2016
  • Sicca Syndrome (Sjogren) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Sicca Syndrome (Sjogren), H1 2016
  • Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top